Microbioz, February 2021: India

2
Microbioz India, February 2021

16
42
14 26
24
Cover Story 10
Future Hospitals: New therapy approaches for the patient
Featured Article
Combined heart and lung transplant and Bilateral lung transplant gives new 12
lease of life to two patients at Aster Hospitals, Bangalore
Business News 21
Philips highlights central role of healthcare in the
home at CES Digital 2021
Product Launches 35
Zeiss Enhances Field Emission SEMs for Sub-nanometer Imaging, Analytics
ebulization is a common and alternative method of drug
delivery to the lungs. It is largely used in clinical settings for
the treatment of acute respiratory ailments as well as for the
long-term treatment of obstructive airway diseases such as
chronic obstructive pulmonary disease, asthma, cystic fibrosis
and bronchiectasis.
The cover story of this month titled “Nebulization is safe, say

experts” contributed by Mediawire a case study which mainly
focuses on Nebulization safe practices, the article explains
the view of Indian Chest Society (ICS), over the use of
Nebulization, the apex body of pulmonologists in India,
appointed a task force to gather all the updated available
evidence to come out with a guidance document for
physicians. The said guidance was recently made available
online ahead of print.
Added to this, the magazine has a unique article as a case

study of Aster Hospital entitled “High Efficiency Aerosol Drug
Delivery During Ventilation” contributed by Aerogen-
Pioneering Aerosol Drug Delivery. Aerogen devices are highly
efficient vibrating mesh aerosol drug delivery systems which
can be used inline during any type of respiratory support
including mechanical ventilation, high frequency oscillatory
ventilation (HFOV), non-invasive ventilation (NIV), continuous
positive airway pressure (CPAP) and High Flow Nasal Cannula
(HFNC)1-4, 7, 20, 23.
Dear subscribers, I trust you to discover some exciting topics

in the magazine. Additionally, I might want to express
gratitude toward you for being together on this beautiful
excursion up until this point. We couldn't expect anything
more than to have your significant criticism and proposals as
they help us to think of better substance each time. For any
suggestion and feedback please feel free to write:
editor@microbiozindia.com
Disclaimer:
Neither the Microbioz India nor its publishers nor anyone else involved in
creating, producing or delivering the Microbioz India (in printed, web or CD
format) or the materials contained therein, assumes any liability or responsibility
for the accuracy, completeness, or usefulness of any information provided in the
Microbioz India Magazine (in printed, web or CD format), nor shall they be liable
for any direct, indirect, incidental, special, consequential or punitive damages
arising out of the use of the Microbioz India magazine. Microbioz India, February 2021
Cover Story
Nebulization
is Safe, Say Experts
uring these unprecedented times, a Dr G C Khilnani from Delhi, Dr Neeraj Gupta
D
lot of misconceptions have arisen from Ajmer and Dr Indranil Halder from Kolkata
related to lung health and its are other co-authors.
treatment, including the role and Nebulization therapy has been frequently used for
use of nebulisation therapy. In view controlling acute asthma attacks, chronic
of this, Indian Chest Society (ICS), obstructive pulmonary disease (COPD)
the apex body of pulmonologists in
exacerbations, and for home maintenance
India, appointed a task force to gather all the
updated available evidence to come out with a
treatment for respiratory diseases like cystic
guidance document for physicians. The said fibrosis, bronchiectasis, etc. Nebulizers are useful
guidance was recently made available online ahead in patients who are unable to use an inhaler (such
of print. as elderly patients) or need a large dose of an
The released guidance document talks about inhaled medication.
nebulization during the pandemic, not only in the The authors clarified that nebulization is
hospital but also at home. The lead and categorized as low to medium risk as far as Covid
corresponding author of this clinical commentary 19 spread is concerned.
is Dr Rajesh Swarnakar from Nagpur while Prof
Microbioz India, February 2021 10

Cover Story
ICS guidelines state that the use of traditional face Dr Mishra, further added, "Creating awareness
mask during nebulization should be avoided during about the safe use of nebulization therapy and
the pandemic, especially while treating Covid 19 imparting knowledge to empower the doctors,
patients. paramedics, caregivers, and patients to manage
nebulization better has become very crucial in these
Instead, jet nebulizers are recommended to be used times. The first step is to consult a doctor before
with a mouthpiece. starting nebulization therapy."
The guidance document was shared recently by Dr
Rajesh Swarnakar, National Secretary of ICS, in a "COVID times have led to re-evaluation of many
live webinar organized for physicians across the essential practises. In the Respiratory arena, the
country. Many doctors across India shared the initial fear of aerosols needs to be looked at again
similar views with ICS and stated their option on so as to not deprive people of essential aspects such
recent guidance. as nebulization. This is especially true when the
Dr Swarnakar clarified that nebulization is benefit outweighs the risk." Added Dr Mishra.
categorized as low to medium risk as far as Covid Additionally, when COVID prevalence diminishes
19 spread is concerned. ICS guidelines state that the in the community, these practices can be done
use of traditional face mask during nebulization similar to pre-COVID times. In the winter period,
should be avoided during the pandemic, especially appropriately done nebulization is an invaluable
while treating Covid 19 patients. tool to prevent worsening, keep patients at home
and avoid hospitalization.
Instead, jet nebulizers are recommended to be Nebulization at home should be performed with all
used with a mouthpiece. safety precautions such as using a clean nebulizer in
According to Dr Rajesh Chandra Mishra, Honorary a well-ventilated room and disinfecting the
Consultant Intensivist & Internist, Ahmedabad, nebulizer after every use. It is RECOMMENDED
to NOT share the nebulizer between family
General Secretary ISCCM (2019-2020) stated,
members. To prevent the spread of infection, every
"Asthmatic patients with no symptoms or no nebulizer should be a single person use nebulizer.
confirmed diagnosis of Covid 19 can continue with A patient can also opt for a disposable nebulizer
essential nebulized medications, as accessory. Cleaning and disinfection of nebulizer
recommended by their physician. Standard pre and post nebulization is a must!
guidelines like maintaining safe distance and Note: This story is provided by Media wire only.
washing hands must be followed. A fresh mask, Disclaimer: The views expressed in the article above are those of the
mouthpiece and tubing should be preferred for authors' and do not necessarily represent or reflect the views of this
publishing house. Unless otherwise noted, the author is writing in his/her
each nebulization treatment." personal capacity. They are not intended and should not be thought to
represent official ideas, attitudes, or policies of any agency or institution.

Featured Article
High Efficiency Aerosol Drug Delivery

During Ventilation
erogen devices are highly efficient patients in the inspiratory limb) and before the
A
vibrating mesh aerosol drug delivery humidifier2 (Figure 1).
systems which can be used inline during While the Ultrasonic nebuliser efficiency is
any type of respiratory support including comparable to the Aerogen Solo at the Y, there are
mechanical ventilation, high frequency many limitations with the device which include an
oscillatory ventilation (HFOV), non- inability to aerosolise viscous solutions, heat
invasive ventilation (NIV), continuous positive generation which can degrade some solutions and
airway pressure (CPAP) and High Flow Nasal large residual volumes21. Furthermore, the use of
Cannula (HFNC)1-4, 7, 20, 23. ultrasonic nebulisers is now minimal in the
hospitals.
Figure 1: Comparison of drug deposition after aerosol therapy through a ventilation circuit with standard small volume
nebulisers, ultrasonic and the Aerogen Solo. The position of the nebuliser tested included: at the wye and before the
humidifier (closer to the ventilator). In this paediatric model of mechanical ventilation with bias flow the Aerogen Solo
outperforms both small volume nebulisers in both positions in the ventilator circuit. *p<0.001. Adapted from 2.
The Aerogen Solo utilises active vibrating mesh This difference in aerosol deposition related to
technology, where energy applied to the vibrational positioning was originally studied by Ari et al. and
element, causes vibration of each of the 1000 demonstrated improved deposition when the
funnel shaped apertures within the mesh. The mesh Aerogen Solo was placed before the humidifier
acts as a micropump drawing liquid through the compared to at the wye with both adult and
holes producing a low velocity aerosol optimised paediatric settings when utilising a bias flow1;
for targeted drug delivery to the lungs. without bias flow improved aerosol deposition was
noted when the nebuliser was positioned closer to
The Aerogen device can deliver 9 times more the patient22.Physiological lung dose was studied in
aerosol dose compared to standard small volume- an infant animal model, where quantification of
nebuliser during mechanical ventilation2, and radiolabelled aerosol was measured after inhalation
outperforms all standard small volume nebulisers through a ventilator circuit, tested with both a small
when positioned at both the wye (proximal to the volume nebuliser and the Aerogen Pro.

Featured Article
The Aerogen Pro demonstrated a 25-fold higher References:
deposition of aerosol in the lungs compared to a
standard small volume nebuliser13.  Ari A, Atalay OT, Harwood R, Sheard MM, Aljamhan EA
and Fink JB. Influence of nebulizer type, position, and bias
flow on aerosol drug
delivery in simulated pediatric and adult lung models during
mechanical ventilation. Respiratory care. 2010;55:845-51.
 Berlinski A and Willis JR. Albuterol delivery by 4 different

nebulizers placed in 4 different positions in a pediatric
ventilator in vitro model. Respiratory care. 2013;58:1124-33.
 Fang TP, Lin HL, Chiu SH, Wang SH, DiBlasi RM, Tsai YH
and Fink JB. Aerosol Delivery Using Jet Nebulizer and
Vibrating Mesh Nebulizer During High Frequency
Oscillatory Ventilation: An In Vitro Comparison. Journal of
aerosol medicine and pulmonary drug delivery. 2016.
 Abdelrahim ME, Plant P and Chrystyn H. In-vitro
characterisation of the nebulised dose during non-invasive
ventilation. The Journal of pharmacy and pharmacology.
2010;62:966-72.
 Galindo-Filho VC, Ramos ME, Rattes CS, Barbosa AK,
Brandao DC, Brandao SC, Fink JB and de Andrade AD.
Radioaerosol Pulmonary Deposition Using Mesh and Jet
Nebulizers During Noninvasive Ventilation in Healthy
Subjects. Respiratory care. 2015;60:1238-46.
 McPeck M. Improved Aerosol Drug Delivery with an

Electronic Mesh Nebulizer during Non-invasive Ventilation
AARC poster. 2012
Figure 2: - Lung Scintigraphy images of a ventilated infant  Ari A, Harwood R, Sheard M, Dailey P and Fink JB. In vitro
comparison of heliox and oxygen in aerosol delivery using
animal model after inhalation of radiolabelled aerosol using pediatric high flow nasal cannula. Pediatric pulmonology.
2011;46:795-801.
either a small volume nebuliser or the Aerogen Pro. The  Reminiac F, Vecellio L, Heuze-Vourc’h N, Petitcollin A,
Aerogen Pro delivered a significantly greater lung dose than Respaud R, Cabrera M, Le Pennec D, Diot P and Ehrmann
S. Aerosol Therapy in Adults Receiving High Flow Nasal
the small volume nebuliser. Adapted from 13. Cannula Oxygen Therapy. Journal of aerosol medicine and
pulmonary drug delivery. 2015.
 Alcoforado L, de Melo Barcelar J, Castor Galindo V,
Cristina S. Brandão S, Fink J, B. and Dornelas de Andrade
A. Analysis of Deposition Radioaerosol Nebulizers
Membrane in Healthy Subjects. ISAM poster presentation
2015.
 Ari A, de Andrade A, Sheard M, AlHamad B and Fink
JB. Performance Comparisons of Jet and Mesh Nebulizers
Using Different Interfaces in Simulated Spontaneously
Breathing Adults and Children. Journal of aerosol
medicine and
 pulmonary drug delivery. 2014.
 Dugernier J, Reychler G, Depoortere V, Roeseler J,
Michotte JB, Laterre PF, Jamar F and Hesse M.
Tomoscintigraphiccomparison of lung deposition with a
vibrating-mesh and a jet nebulizer. ERS conference poster
2015.
 Hickin S, Mac Loughlin R, Sweeney L, Tatham A and
Gidwani S. Comparison of mesh nebuliser versus jet
nebuliser in simulated adults with chronic obstructive
pulmonary disease. Poster at the College of Emergency
Medicine Clinical Excellence Conference. 2014
The Aerogen Pro achieved a lung dose of 13% and
the difference in aerosol deposition between the
two systems can be clearly observed in the For further information, please contact:
Kamal Kishore
scintigraphy pictures below (Figure 2)13. Business Manager -India
Tel: +91 9971700662
kkishore@aerogen.com
The superior drug deposition available with
Aerogen is associated with the minimal residual Rajiv Julka
volume left in the device after nebulisation. Country Manager -India & Subcontinent
Tel: +919810093138
Standard small volume nebulisers on average leave rjulka@aerogen.com
up to half of the drug behind which can be quite
costly when using more expensive drugs24. Dubus
et al. observed that the standard small volume
nebuliser has a residual volume of 1.1 mL after
nebulisation of 3-mL of solution. In contrast the
Aerogen Pro had a residual volume of 0.1 mL after
0.5-mL13.

Featured Article
All you need to know

about Breast Cancer
he most common cancer amongst We have been witnessing a surge in breast cancer
women, breast cancer covers 25% of cases amongst women in the age group of 25-49
T all cancer burden, globally as well as in

India. With alarming rise in its
incidence in the
predominantly in urban India,
country,
estimates suggest every four minutes an Indian

woman is diagnosed with breast cancer and every
years in India.
While genetic predisposition is a prominent risk
factor, it is not the only one. Lifestyle and
environment factors too could be at play. Hence, it
is important for women for all ages to pay attention
13 mins a woman dies due to the condition. to their breasts and regularly examine them. Timely
diagnosis and treatment at early stages of breast
According to a recent report by WHO and
International Agency for Research on Cancer cancer can go a long way in improving the survival
(IARC), India saw 162,468 women newly detected rates.
with breast cancer and 87,090 losing their lives to Myth 2: Leading an active and healthy lifestyle will
the disease in 2018.
keep breast cancer at bay
While genetic predisposition, sedentary lifestyle,
Yes, staying active and eating nutritious food is
longer working hours, late pregnancy, smoking,
helpful to keep the body healthy and to lower risk
excessive alcohol consumption, stress and obesity
of various disease conditions including breast
are some of the risk factors associated with breast
cancer but it can’t eliminate it. It is critical to watch
cancer. Medical experts believe delayed diagnosis out for warning signs such as lump in the breast or
and lack of awareness are major reasons for its high
underarm, thickening or swelling in the breast, pain
mortality rates. Most women do not know enough
and redness in the nipple areas, dimples or bulges
about breast cancer to get themselves diagnosed
on the breast skin and nipple discharge. If you
early.
notice any unusual changes, it is recommended to
This World Cancer Day, Dr. CB Koppiker, consult a doctor. A self-examination of the breast,
Breast Onco-surgeon and Medical Director at regular screening with mammography, ultrasound
Orchids Breast Health Center, Pune, debunks is beneficial for early detection of the cancer.
various myths related to the condition and its
Myth 3: Lumps around breast indicates breast
management.
cancer
Myth 1: Breast cancer usually happens in older
No, a lump or lumps in the breast area doesn’t
women and those with family history necessarily mean its cancer. Lumps can be formed
It is true that elderly women may be at a higher risk due to various reasons including infection,
for developing breast cancer, but it can occur in inflammation, hormonal changes, trauma, tumor,
younger population as well. etc. Breast cancer might or might not cause a lump.

Featured Article
So, if you discover a new breast lump do not ignore Myth 5: Breast cancer means removal of the entire
the change or panic, instead get it checked by a breast
doctor. Annual clinical breast exam and
mammography is recommended for those above A radical mastectomy or surgical removal of the
30 years of age. entire breast is suggested only when the cancer has
spread extensively to the chest muscles. For each
Myth 4: Treatment for breast cancer is same for all patient, the course of treatment varies per the
cancer stage and his/her condition. With surgical
Management of breast cancer depends on the
advances breast conservation surgeries are a norm
severity/stage of the disease and the patient’s
today. During a skin/nipple sparring surgery,
preference. In breast cancer, information about
surgeons remove only the cancer-affected breast
whether the cancer has spread from primary tumor
tissues/tumour and re-construct the breast.
location to other locations is very critical. During
Fluorescence Imaging helps surgeons to assess the
the minimally invasive biopsy, technological
vascularity of the skin flaps during surgery allowing
advancements like fluorescence imaging enables
them to ensure that the skin or the nipple areolar
surgeons to selectively remove the lymph nodes
flap that are left behind after nipple sparring
and improve clinical accuracy of cancer staging.
mastectomy are safe enough for reconstruction.
Enhanced precision and selected removal help
avoid post-op complications like lymphedema, References:
sensory deficit, pain, and impaired arm movement.
https://www.forbesindia.com/article/weschool/why-breast-cancer-
Treating breast cancer may involve surgery, awareness-needs-better-marketing-in-india/63939/1
chemotherapy, radiation, and hormone therapy. https://www.breastcancerindia.net/statistics/latest_statistics_breast_cance
r_india.html
https://www.who.int/cancer/PRGlobocanFinal.pdf

Interview
“The science of
genomics and
metabolic disorders
was rapidly evolving
which further facilitated
diagnostics and
therapeutics of
undiagnosed diseases
thus we had a whole
new world of Rare
Diseases unfolding.”
Here I am sharing an Interview Dr. Ashok Gupta, Professor of Pediatrics, Incharge Rare Disease,
with Dr. Ashok Gupta, SMS Medical College, Jaipur
Professor of Pediatrics,
Incharge Rare Disease, SMS Medical College, Jaipur, India
What prompted you to become a doctor & why did How do you like to be recognized for your hard
you choose this specialization? work?
Human physiology always fascinated me, as a There is no specific modality of getting to be
young student I dreamt of understanding the recognized in some instances it is just a small social
variables that produced different clinical responses appreciation or it may be that i get nominated to
amongst different individuals and also how important decision making body on Rare Diseases,
suffering could be minimized. After doing my any major journal publishing my case report and
specialization in Pediatrics, I was exposed to a lot above all the smile on the face of my patients and
of undiagnosed diseases which became the starting their families.
point of my tilt towards Rare Diseases.
How do you try and create a great patient
The science of genomics and metabolic experience?
disorders was rapidly evolving which For a great patient experience i would spend time
further facilitated diagnostics and to research to reach to a good diagnosis which also
therapeutics of undiagnosed diseases thus involves multiple organizations teaming up to
provide free or subsidized investigational cost. Also
we had a whole new world of Rare coordinate the access to treatment at an affordable
Diseases unfolding. price.
Thus, the novelty and the challenges brought me What is a rare disease and how does it affect
into this specialty. patients?
A rare disease is one which affects very few people,
there are over 7000 rare diseases.

Interview
The manifestations are varied and range from How has COVID impacted the treatment course
dysmorphology to low blood sugar to convulsions for rare disease patients?
to mental retardation to blood/joint/skin...protean
manifestation. Covid phase made travel very difficult and many
patients could not reach the hospitals. Even the
What are the challenges that rare disease patients transport of diagnostic samples and treatment
face in India? medicines suffered.
There are multiple challenges that rare disease There is a renewed impetus on Healthcare
patients face, lack of trained medical personnel, infrastructure. What kind of support do you think
poor access to diagnostics, delayed diagnosis, there can/ should be for the Rare disease burden
highly expensive investigations and therapy in most
in India?
instances. Non availability of Medicines, inadequate
social and governmental support. There is an urgent need to establish regional centers
of excellence where in all possible investigations
What are the challenges you face while should be done. A good transport facility and
diagnosing Pediatric cases? proper network of the regional centers need to be
The challenges faced at my end are essentially done.
financial constraints both for diagnostics and
therapeutics. The turnaround time for
investigations should also come down.

Business News
Godrej & Boyce aims to strengthen Vaccine Cold Chain

till the last mile, for India and the World
 Unveils ‘Made in India, for the world’ ultra-low-temperature freezers (below -80 °C),
expanding its existing portfolio currently deployed in India’s Covid Vaccination Drive.
 With advanced vaccine cold storage technology, Godrej & Boyce makes India
atmanirbhar and ready, for vaccines of the future
 Partner to ongoing Covid Vaccination Drive in India, Godrej & Boyce ready for last
mile Covid vaccine deployment
odrej & Boyce, the flagship company The mRNA-based Covid 19 vaccines are extremely
G of the Godrej Group, has been

contributing to making India self-
reliant since its inception. Taking a
step further towards building the
nation’s healthcare infrastructure,
Godrej & Boyce through its business unit Godrej
Appliances, has been partnering the ongoing Covid
temperature-sensitive as well and must be stored at
very cold temperatures. mRNA is constantly at risk
of being destroyed by other molecules in the
environment. Although manufacturers of the
vaccines have made chemical changes to the
synthetic mRNA and wrapped it in a protective
layer, they need to be stored at temperatures as low
vaccination drive in India through its advanced, as below -80°C, to prevent wastage of vaccines,
made in India, medical refrigeration solutions which has a direct implication on human health.
which safeguard the sensitive vaccines at just the
right temperature. Today, it added state of art ultra-
low temperature freezers to its portfolio,
strengthening the vaccine cold chain further. These
advanced medical freezers can preserve life-saving
medical supplies including critical vaccines below -
80°C and are aimed at boosting both Indian and
global medical cold chain.
Godrej Appliances is currently deploying vaccine
refrigerators which maintain a precise temperature
of 2 to 8°C to store the highly temperature sensitive
Covaxin and CoviShield vaccines being Godrej Vaccine Refrigerators being
administered in India, as part of the national tender manufactured at its Shirwal plant
it received in October 2020. Medical Freezers
which maintain -20°C are also being deployed for
diluents and ice packs needed for the last mile Hence, any wastage or inefficiency in the
delivery in the Covid vaccination drive. The vaccination process due to logistical issues related
vaccines run the risk of damage if they are subjected to cold chain must be avoided. The operating
to fluctuations beyond the specified temperature principle for the Godrej Ultra Low Temperature
band, leading to both health and economic freezer is a cascading system having a PHE (Plate
implications. heat exchanger) as a heat exchanger between the
The ultra-low temperature freezers are a new primary and the secondary system. This lowers the
addition to this portfolio and are particularly suited standing pressure of the secondary system leading
to mRNA based vaccines which are being deployed to lowering of temperature. Additionally, Godrej
in other countries currently. Ultra Low Temperature Freezers have inbuilt safety
systems with alarms to protect secondary
compressor in case of unlikely pressure build up.

Business News
Features like (a) 2 step sealing & Internal separate and life-saving supplies that can help governments
doors to help avoid temperature ingress and (b) Oil across the world in their fight against the covid-19. This
recovery for secondary system for long running, pandemic has underscored the need to be future ready
boost the overall efficiency of the unit during when it comes to vaccine cold chain infrastructure. As
operation. Furthermore, back-up systems like a group we are constantly transforming to get newer
Liquid CO2 or Liquid NO2 ensure safety of stock technologies and partner to make the nation self-
stored, by maintaining a stable temperature for over reliant. Our latest offering of Ultra Low Temperature
48 hours, in case of a power outage or an unlikely Freezers will help make India more ready for vaccines
system failure. of the future as well. This endeavor also brings alive
The current capacity for Ultra Low Temperature our ethos of Made in India for the World.”
Freezers is 12,000 units per annum, which Godrej Commenting on these developments, Mr. Kamal
Appliances is working towards quickly ramping up Nandi, Business Head and Executive Vice
to 30,000 units per annum, to meet the growing President, Godrej Appliances said,
global demand.
“We are glad that we have been able to apply our
Godrej Appliances is also exploring other ways to refrigeration expertise in developing a strong vaccine
assist in the next phase of vaccine deployment till cold chain in India at a critical time. Our medical
the last mile. It has successfully piloted a mobile refrigerators and medical freezers deliver the precise
clinic in rural Maharashtra, running an ambulance cooling temperature of 2°C - 8°C and -20°C
equipped with a vaccine refrigerator, without respectively, needed for the vaccines being
connecting it to a power source for three days. The administered by India currently. Now, with our newly
temperature was monitored every 2 hours and met launched range of advanced ultra-low temperature
the required temperature norms. As India
freezers, which can provide a temperature of below -
accelerates the pace of vaccinations, more agile
80°C, India will also have the storage solutions readily
remote deployment may hold the key to success.
available, for other Covid-19 vaccines being deployed
Godrej & Boyce has been committed to serving the across the world. We are partnering with various
country especially in the trying pandemic times, stakeholders in strengthening the healthcare cold
through its diverse offerings – be it through chain and aiming to assist in other potential vaccine roll
medical components - Hospital Bed Actuators and out challenges - like through mobile clinics for last mile
Electro-magnetic valves for ventilators, or through vaccine deployment in remote areas, for the next
disinfectant devices aimed at keeping the phase of Covid-19 vaccine inoculation.”
population safer at home, or setting up socially About Godrej & Boyce: Godrej & Boyce (‘G&B’), a Godrej Group
distant offices to keep people safe at work; and is company, was founded in 1897, and has contributed to India’s journey of
proud to serve not just the country but the world self-reliance through manufacturing. G&B patented the world’s first
springless lock and since then, has diversified into 14 businesses across
with Made in India medical refrigerators, freezers various sectors from Security, Furniture, Appliances, Aerospace to
and ultra-low temperature freezers, at a time when Infrastructure and Defence. Godrej is one of India’s most trusted brands
they are most needed. serving over 1.1bn customers worldwide daily.
About Godrej Appliances: Godrej Appliances, a business unit of Godrej

Commenting on the recent developments, Mr. & Boyce, is one of the leading Home Appliances players in India. Godrej &
Jamshyd Godrej, Chairman and Managing Boyce was the first Indian Company in 1958 to manufacture Refrigerators
Director, Godrej & Boyce Manufacturing and since then Godrej Appliances has expanded its portfolio across many
other categories like Washing Machines, Air Conditioners, Microwave
Company Ltd. said, “Depth of coverage and Ovens, futuristic Thermo-electric cooling solutions, Air Coolers, Deep
sustenance of Covid-19 vaccination drive will be key to Freezers, highly specialized Medical Refrigerators and more recently, UVC
Technology-Based Disinfecting devices and Dishwashers, all powered by
ward off further spread of the pandemic. Today, the driving philosophy of 'Things made thoughtfully’.
nations across the globe are facing challenges in
This thought extends from human-centric design to planet centric design.
running effective covid-19 vaccination programs.
Environment is a core value at Godrej. Both manufacturing units of Godrej
Inadequate cold chain equipment is one of the key Appliances became the first in the country to win the coveted Platinum Plus
challenges, which can lead to inefficacy of the vaccines Green Co certification for their pioneering green manufacturing practices.
and cost human health. With Godrej’s decades of The brand takes pride in not just its carefully designed products and
expertise in refrigeration technology, the brand offers a environment-friendly technologies, but also best in class after-sales service
delivered through over 680 service centers and more than 4500
range of advanced cold storage solutions for vaccines SmartBuddy service experts spread all over the country.

Business News
Aster DM Healthcare launches a dedicated

‘Women and Children Care Hospital’ at
Whitefield, Bangalore
ster DM Healthcare, one of the largest DM Healthcare is happy to announce the opening
integrated healthcare service networks of the Phase 1 part of our 350-bed Aster Whitefield
A in the GCC and the third largest

healthcare company in India, has
announced the launch of its 49 bedded
dedicated ‘Women and Children Care
Hospital’ at Whitefield, Bangalore. Comprising of
14 bedded Neonatal Intensive Care Unit (NICU)
project, our latest offering to the Garden City of
Bengaluru. The Phase 1 part consists of a boutique
Women and Children hospital that has best in-class
technology and equipment backed by an eminent
clinical faculty. While the entire Aster Whitefield
project envisages a total investment of Rs. 200
and a 7 bedded Pediatric Intensive Care Unit crore, this phase 1 launch of the Women &
(PICU), this hospital will offer cutting edge Children Hospital has been established at an
multidisciplinary women and child care that will be investment of Rs. 25 crore. Aster is also looking at
steered by highly skilled medical professionals further expansion of our Kolhapur Hospital in
Maharashtra called
Aster Aaadhar,
wherein we are
adding extra 60 beds
to the existing bed
capacity of 180 and
also includes a new
comprehensive
Oncology Block.
The investment for
this expansion is Rs.
35 crore.”
“With a history of
over 32 years of
care, our team of
highly experienced
dedicated to providing world-class care and highest experts will offer advanced treatments to patients
safety standards. using cutting-edge diagnostic and therapeutic
The new unit offers a wide number of specialties technology. The dedicated women and child
that include gynecology, paediatrics, paediatric hospital is standalone concept hospital that will be
superspeciality, neonatology, fetal medicine and supported by a large multi-specialty hospital. The
24/7 emergency care. The other different facilities availability of a multi-specialty support can become
and services available at the hospital includes an indispensable entity for the expecting mothers
labour delivery suites, Modular Operation Theatre, and can prove to be a life-saviour for both the
Cardiotocography Monitoring for a foetal mother and the child care at all stages and beyond.
heartbeat, 3D and 4D Ultrasound, Paediatric ICUs, At Aster, we strive for excellence, every moment
Neonatal ICUs, X-Ray, Birthing Suites, and a 24*7 and every day – to bring great healthcare within
Walk in Pharmacy.Commenting on the reach of people. We live by our motto We’ll Treat
establishment of the hospital, Dr. Harish Pillai, You well to the last detail.” said, Dr. Nitish Shetty,
Chief Executive Officer, Aster India, said: “Aster CEO, Aster Hospitals, Bangalore.

Business News
Fortis brings together Cancer Survivors, shares

stories of hope & joy!
n the occasion of World Cancer Day courage to the cancer patients and their care givers
(February 4th), Fortis Cancer Institute who are currently undergoing cancer treatment.”
O undertook a distinctive approach to

celebrate cancer survivors and inspire the
patients who are recently diagnosed with
cancer. A series of activities were held for
cancer survivors and their caregivers to address the
less discussed issues in cancer at Aasha, a cancer
Commenting on the initiative, Dr. Mohan
Keshavamurthy –Director- Department of
Urology- Urology, Uro-oncology, Andrology -
Transplant & Robotic Surgery, said, “It gives us
immense pleasure to see our patients completely
recovered and leading a healthy life. Through
support group
initiated by
Fortis Cancer
Institute,
Bangalore.
Aasha, is a
place for
celebrating the
courage and will
power of cancer
survivors and to
inspire those
who are
recently
diagnosed. At
Aasha, a 90-
minute
interactive
session is conducted with doctors, support group Aasha, we are able to meet our patients again and
team and survivors which is followed by yoga hear their stories of leading a happy and cancer free
session, session on power of healthy eating and life. As we are putting the survivors and cancer
concluded by some music therapy. As part of the patients both on the same platform, it will help
session, cancer survivors and their caregivers also encourage and motivate the recently diagnosed
share their experiences of battling cancer to patients in their cancer journey.”
encourage the recently diagnosed cancer patients.
Aasha would be an ongoing monthly activity which To highlight the importance of therapy like yoga &
will be conducted with different patients each music will also be a part of the session.
month with Yoga/ Music sessions for them.
Dr. Niti Raizada, Director - Medical Oncology About Fortis Healthcare
and Hemato-Oncology- Fortis Cancer Fortis Healthcare Limited – an IHH Healthcare Group Company – is a
Institute, said “On the occasion of World Cancer Day, leading integrated healthcare services provider in India. It is one of the
largest healthcare organisations in the country with 36 healthcare facilities
we take the opportunity to introduce Aasha an initiative by (including projects under development), 4000 operational beds and over
Fortis Cancer Institute. This Cancer Support group will 400 diagnostics centres (including JVs). Fortis is present in India, United
serve as a platform for cancer survivors as well as the cancer Arab Emirates (UAE) & Sri Lanka. The Company is listed on the BSE Ltd
and National Stock Exchange (NSE) of India. It draws strength from its
patients to understand the importance of healthy living with partnership with global major and parent company, IHH, to build upon its
the help of yoga session, and a session on healthy culture of world-class patient care and superlative clinical excellence. Fortis
eating. employs 23,000 people (including SRL) who share its vision of becoming
the world’s most trusted healthcare network. Fortis offers a full spectrum of
While, we also urge cancer survivors to share their integrated healthcare services ranging from clinics to quaternary care
journey of fighting cancer that would give hope and facilities and a wide range of ancillary services.

Business News
Hunjan Hospital launches Mako Robotic Arm-

Assisted Technology for knee replacement in
Ludhiana
udhiana reached an important milestone outcomes and making healthcare better makes our
in knee replacement as it became the first partnership with the hospital very special.
L city in Northern India to have the world’s

most widely adopted US FDA approved
Mako Robotic Arm-Assisted
Technology. The first Mako System in
Northern India has been installed at Hunjan
Hospital, said a press release issued jointly by
We are truly excited about the potential impact on
serving patients needing knee replacement across
Northern India.”
Dr. BS Hunjan, Director and Joint Replacement
Surgeon at Hunjan Hospital, while talking about
Stryker India, a leading global medical device the difference between conventional and Mako
company, headquartered in the US, and Hunjan Robotic Arm-Assisted Surgery during the press
Hospital, a renowned orthopedics hospital in the conference held in Ludhiana, explained that one of
city of Ludhiana. the challenges with traditional surgery is that
surgical accuracy depends on the surgeon’s
The launch comes as an important milestone for
Hunjan Hospital and Stryker, in their endeavor to experience and technique. Mako Robotic Arm-
bring the most advanced technology and treatment Assisted Surgery System allows surgeons to make
precise bone cuts on the diseased joint, every single
for patients suffering from knee joint disorders.
Mako Robotic Arm-Assisted Surgery System time.
enables surgeons to deliver more predictable “First 8 patients that we operated on have shown
surgical outcomes with increased accuracy. encouraging results. With Mako, we have been able
Congratulating Hunjan Hospital on this to know more about our patients than ever-before
important milestone, Ms. Meenakshi Nevatia, and we are able to cut less.
the Vice President and Managing Director of For some patients, this can mean less soft tissue
Stryker India, said, “We are very happy to partner damage and for others greater bone preservation.”
with Hunjan Hospital and it is indeed a proud
moment for Stryker. Our common vision of
bringing newer innovations to improve patient

Business News
Dr. Jaiveer Hunjan, Consultant Orthopaedics at This planning, done even before entering the
Hunjan Hospital further added, “While operation theatre, helps in deciding the most
conventional knee replacement surgeries have been accurate bone cuts and alignment of implants.
improving life of patients effectively over last three
decades, the Mako System will enhance our The technology allows the surgeon to modify the
accuracy significantly. As suggested by the literature plan during the surgery, if required. And once the
and our experience with initial surgeries, we have plan is locked, the Mako Robotic Arm-Assisted
seen tremendous patient benefits such as precise Surgery System assists the surgeon in executing
planning and bone cuts, more bone and soft the bone cuts in the operation theatre. The unique
tissue preservation, less post-op pain, faster haptic technology ensures that the surgeon
recovery, quicker discharge and less blood
remains within the virtual boundaries created.
loss.” Speaking on the technology, Dr. BS Hunjan
Since the robotic arm cannot be physically moved
said, “This technology has the potential to
transform the way knee replacement surgeries are outside the virtual boundary, it enables the
performed. I am sure a day will come when this preservation of soft tissue. This allows most
technology will be a Standard of Care in every accurate bone cuts, positioning of implants and
operating room. We are very proud to bring world protecting any injury to soft tissue.
class care to the doorstep of patients in Punjab.”
The largest global install base of more than 1,000
Mako Systems (and counting), more than 350,000
Mako procedures and more than 145 publications
in published, peer reviewed studies establish the
clinical prowess of Mako Robotic Arm-Assisted
Technology.
For more information:

sandhya.nair@stryker.com
About Stryker
Each patient’s bone anatomy is different, and Stryker is one of the world’s leading medical technology companies
arthritis further tends to alter the diseased joint. In and, together with its customers, is driven to make healthcare
case of a knee or hip surgery, Mako System’s better. The company offers innovative products and services in
software helps create a 3D model of the diseased Orthopaedics, Medical and Surgical, and Neurotechnology and
joint based on the patient’s CT scan. The software Spine that help improve patient and hospital outcomes. More
information is available at stryker.com.
then allows creating a personalized virtual surgical
plan for each patient, based on their specific disease
condition.

Business News
100+ corporates sign up for Practo’s corporate health

plans to promote employee well-being
 Practo’s corporate health plans, which offer a myriad of integrated healthcare services,
witnesses a surge of over 35% since March 2020
 L&T financial services, Marico, Hexaware Technologies,Tata Realty, Denave India, and Telus
International are among the companies that have availed the Practo plans for their
workforce
racto, India’s leading integrated Through Practo, employees of the partnered

healthcare company, has witnessed a companies can have 24*7 access to 25,000+
P significant growth in the demand for

its corporate health and wellness
plans, with over 100 corporates
signing up for them in 2020. The
increase in sign-ups is recorded as
organizations continue looking at strengthening
employee-safety initiatives and providing them
doctors for instant online consultations across 22+
specialties on the ‘Practo Plus’ health plan network.
With a response time of about 120 seconds,
thousands of employees have availed online
consultations so far. GP, dermatology,
gastroenterology, gynaecology, pediatrics,
psychiatry, and cardiology are among the most
with easy access to healthcare in response to the
COVID-19 pandemic. L&T financial services, consulted specialities.
Marico, Hexaware
Technologies,Tata
Realty, Denave
India, and Telus
International, are
among the
companies that
Practo currently
extends its services
to.
Buoyed by the
positive response
for the corporate
health plans, Practo
is looking at
covering the healthcare needs of 2.5 lakh
employees by the end of 2021. To drive this, Practo
Thanks to these health plans, companies have seen
will be fully involved and support employers
a significant drop in the number of employees
through different stages - from onboarding to
taking sick leave or being admitted to hospital,
sharing utilization insights. Retaining the current
while their productivity has also improved over
customer satisfaction score of 4.7/5 across
time. Furthermore, employees could get their
organizations by providing them with quality
medicines delivered to their doorstep.
service will remain Practo’s priority. Since March
2020, Practo’s corporate health and wellness plans In the work-from-home situation, these health
have been used by over one lakh employees and plans enabled employees to address their health
their family members for online consultations with
concerns from the comfort of their home.
verified doctors, preventive health check-ups,
pharmaceutical needs, mental health sessions, and
COVID-19 screenings.

Business News
Elaborating on this trend, Siddhartha Nihalani, VP cover all specialties, along with offering a number
- Product Growth, Practo, said, of benefits. And the best part is that we have
“With people in general trying to make healthier received very positive feedback from our
lifestyles choices in a pandemic-battered world, employees about these health plans.”
corporates are leaving no stone unturned to Based on their requirements, organizations can
ensure employees’ good health and well-being. choose from a variety of packages that Practo
While health insurance plans still form an integral offers. From online doctor consultations to
part of employee benefits, companies have also conducting an ergonomic assessment, Practo’s
started opting for digital healthcare solutions that health plans come with myriad advantages. Other
benefits include annual health checkups, OPD
are accessible, affordable, and safe. In the work-
services, at-home diagnostic services and medicine
from-home situation, teleconsultations catered to delivery covering 16,000 pin codes (depending on
both the physical and mental health requirements the packages).
of employees and their family members.
Convinced by its efficiency and effectiveness, an About Practo:
increasing number of corporates across India are Practo, the country’s leading integrated healthcare company, connects the
switching to Practo’s health and wellness plans.” entire health ecosystem together – patients, doctors, clinics, hospitals,
pharmacy, diagnostics, and other partners, to generate exceptional value
and service for all, esp. the end consumers. It integrates different parts of
Speaking about the partnership, Sanhita Ganguly, the patients’ healthcare journey so they can have one seamless
HR Head, Hexaware, said, experience, right from finding and booking an appointment with verified
doctors, consulting verified doctors online with ETA as low as 60 seconds,
“Since the onset of the Covid-19 pandemic, getting medicine and lab tests at the doorstep, and accessing insightful
health articles authored by verified doctors. Practo also makes software
providing our employees with easy and timely products that help healthcare providers ranging from small clinics to large
access to healthcare has been a challenge. With hospitals digitize and deliver more efficient and higher quality healthcare to
millions of patients around the world.
physical appointments becoming difficult under
current circumstances, the need for online Doctor As technology becomes an integral part of healthcare, Practo has also
become an essential enabler in helping doctors understand the nuances of
consultation has been on the rise. Employees managing and securely storing all health data. Practo encrypts all data with
have become more conscious in choosing the 256-bit encryption, uses HIPAA compliant data centers, and is one of the
few healthcare companies to be ISO 27001 certified. Practo is present in
healthcare benefits and the services provided by 20 countries, helps 18 crore+ patients a year, and connects patients with 1
doctors. This has pushed a need for lakh+ verified doctor partners.
technologically-assisted doctor consulting.

Practo’s corporate health and wellness plans

Business News
Arctoris Celebrates 5th Anniversary and Launches

Its Expanded Robotic Platform Ulysses
rctoris Ltd, an Oxford-based technology This success is the result of our amazing team’s
A
company operating a fully automated dedication and hard work over these past five years,
drug discovery platform, celebrated its combined with guidance from experienced and
5th anniversary on the 4th of February. insightful advisors and board members.
Over the
past five
years, Arctoris has
grown from a
technology startup to a
globally operating
company delivering
integrated drug
discovery projects with
partners on three
continents from its
headquarters in Oxford
and its Asia-Pacific hub
in Singapore. On the
occasion of its 5th
anniversary, Arctoris
unveiled its new and
expanded, next-
generation robotic platform, Ulysses.
We are looking forward to the next five years,
Arctoris was founded in 2016 by Martin-Immanuel which will see even greater change and accelerated
Bittner MD DPhil (CEO) and Tom Fleming growth, toward a future where treatments and cures
MChem (COO), as the world’s first fully automated can be generated at a fraction of the time and cost,
drug discovery platform. Through end-to-end and we are privileged to play our role in building
automation, the company’s unique technology that future”
platform rapidly delivers reliable, reproducible, and
fully auditable datasets enabling better decision- Having strengthened its team over the past few
making early in the drug discovery process. years with several high-profile hires and Advisory
Board appointments, the company has recently
Looking back at the past five years, the company’s announced partnerships with Insilico
CEO Dr Martin-Immanuel Bittner said “The drug Medicine and Syntekabio, while further expanding
discovery ecosystem is evolving rapidly, and the key its operations globally.
to success is having access to the right data at the
right time, to progress the right projects towards Arctoris invited media representatives to an
the clinic. Arctoris plays an important role in exclusive, virtual press event to celebrate its
enabling true data-driven drug discovery globally, anniversary,
by generating the data that powers decisions in
The event featured a presentation by Martin-
biotech and pharma companies on three
Immanuel Bittner outlining the history of Arctoris
continents.”
and trends in the drug discovery market, followed
Tom Fleming, COO of Arctoris, added “Drug by a presentation and live tour of Ulysses by Tom
discovery is undergoing a rapid digital Fleming.
metamorphosis, and Ulysses plays a central
The Chairman of the Board, Dr Vishal Gulati,
catalytic role in that transformation.
echoed the founders’ enthusiasm: “Five years ago,

Business News
the founders set out with the idea to make it About Arctoris ltd:
possible for any scientist in the world to run a
Arctoris Ltd is an Oxford-based technology company that is
biotech company with a laptop and a credit card –
revolutionizing drug discovery for biotechnology companies,
and thanks to Arctoris, this is now entirely possible, pharmaceutical corporations and academia. Arctoris has
harnessing the power of automation for drug established the world’s first fully automated drug discovery
discovery. platform, delivering integrated drug discovery projects with partners
As Chairman of the Board of Arctoris, I am and clients globally. Accessible remotely, the platform provides
access to a wide range of biochemical, cell biology and molecular
incredibly proud of where the Company stands
biology assays conducted by robotics, enabling rapid, informed
today, and I am excited about what lies ahead, on decision-making from target identification to IND filing. These
our path to redesigning drug discovery from the assay capabilities are augmented with a powerful online portal that
ground up.” streamlines experiment planning, tracking and data analysis.
Thanks to the Arctoris platform, drug discovery programs can
progress rapidly, accurately and cost-effectively towards the clinic.

Research News
Hydrogel injection could help fix harm to the

heart muscle after heart attack
esearchers at CÚRAM, the SFI The hydrogel is based on a family of unique
Research Centre for Medical Devices biomaterials, known as elastin-like recombinamers,
R based at NUI Galway, and

BIOFORGE Lab, at the University of
Valladolid in Spain, have developed an
injectable hydrogel which might help
repair and prevent additional damage to the heart
that BIOFORGE-UVa had grown in the search for
innovative hydrogels for regenerative medicine.
“The hydrogel was created to mimic the
environment around the heart after an infarction
and then customized to be able to protect and
muscle following a heart attack occasion.
promote regeneration of the cardiac tissue”, he
The results of their research have only been explains.
published in the prestigious journal Science
Translational Medicine. The therapeutic effect of multiple shots of this
hydrogel into the cardiac tissue was assessed during
Myocardial infarction or heart disease is a leading the first-ever preclinical study of its type,
cause of death because of the irreversible damage demonstrating its efficacy for cardiac tissue
caused to the heart muscle (coronary artery ) during remodeling after a heart attack. The worldwide
a heart attack. The regeneration of cardiac tissue is research team, which included researchers in
minimal so that the damage caused can’t be fixed Ireland, Spain, Sweden, France and Italy, were able
by itself. to show that if their hydrogel was injected into the
heart muscle shortly after a
heart attack, it resulted in less
fibrosis (scarring of the
coronary artery) and an
increase in the creation of
new blood vessels in the area.
They were also able to
observe the increase in the
preservation and survival of
cardiomyocytes, a sort of cell
that allows the heart to
conquer, in the affected area.
Professor Pandit added:”
This project demonstrates
the effectiveness of a
distinctive biomaterial-only
Latest treatments lack an effective procedure to
system able to induce a positive healing effect on
avoid death and subsequent coronary artery repair
cardiac tissue following a heart attack event. The
following a heart attack.
functional benefits obtained by the timely injection
“This project involved the development and testing of the hydrogel supports and highlight the possible
of an elastin-based hydrogel derived from a use of this therapy in the clinic. The next step will
naturally occurring biomaterial in the human be to develop a prototype for a delivery system for
body”, explains Professor Abhay Pandit, Scientific the hydrogel.”
Director of CÚRAM and job lead.

Research News
In this study, we employed a model to specifically look at The recent announcement of a $46M reinvestment
a type of heart attack that has increased in incidence and in CÚRAM by Science Foundation Ireland in
is not often treated until the acute phase resolves. Scar February 2021, demonstrates the Government’s
tissue that forms after the heart attack often remodels strong commitment to the MedTech industry in
negatively, causing future problems like heart failure. The Ireland, encouraging the continuation of
timely injection of this hydrogel appears to change the substantial academic, industry and clinical
way the heart muscle heals after a heart attack. There is collaborations that are central to CÚRAM’s work.
a significant positive histological, biological and functional
recovery of the injured heart muscle. Work is progressing Source:
now to deliver this to the sites of injury in different clinical Science Foundation Ireland (SFI)
settings and will be followed with translation into a clinical
trial.”Mark Da Costa, Study Senior Co-Author and Journal reference:
Professor and Cardiothoracic Surgeon
Contessotto, P., et al. (2021) Elastin-like recombinamers-
CÚRAM’s research focuses on developing based hydrogel modulates post-ischemic remodeling in a
diagnostic devices, biomedical implants, cell-device non-transmural myocardial infarction in sheep. Science
and drug-device combination products to address Translational
Medicine. doi.org/10.1126/scitranslmed.aaz5380
unmet clinical needs.

Research News
Study describes cisplatin-prompted hearing loss in

pediatric cancer growth patients
ermanent hearing loss is a common But the data showed that not all treatment
side effect of the medicine, but until schedules came with the same risk. Children who
P now, studies have been too little and

too varied to accurately characterize
this risk.
Today in The Lancet Child &
Adolescent Health, researchers at Children’s
Hospital Los Angeles published results of the
received higher doses of the chemotherapy were
more likely to experience hearing loss, even when
the complete amount of cisplatin over the course
of the treatment was the same.
The team also uncovered a second, previously
unknown, risk factor for hearing loss: concurrent
biggest analysis of cisplatin-induced hearing loss to use of vincristine, a second chemotherapy agent
date. The analysis establishes the initial benchmarks often added to treatment regimens.
for the prevalence of hearing loss, and reveals that
The team addressed another barrier to
the probability of hearing loss is affected not only
by how much medication is given, but by how that understanding cisplatin-induced hearing loss:
drug is delivered–dosing schedules, complementary variation in distributing audiology scores. Many
international medical centers categorize hearing
treatments, and much more.
loss differently, making direct comparisons
The lot of factors involve means that permanent impossible.
hearing loss can occur in anywhere from 20-
90percent of cisplatin-treated patients. But the new To overcome this issue, the group reviewed all of
the study data using the identical global consensus
study shows that another important aspect of
chemotherapy can affect a child’s risk for hearing system for cisplatin-induced hearing loss
(developed by the International Society of Pediatric
loss.
Oncology), allowing investigators to evaluate
Dr. Orgel and a team of researchers, including hearing loss using over 2,000 tests from patients
CHLA’s Diana Moke, MD, MS, collected treated at 19 unique institutions.
information from over 1,400 patients treated in
hospitals across the USA and Canada. A data pool Uncovering how real-world variables affect risk of side
of this size is no small accomplishment. “Pediatric effects enables oncologists to better serve every child.
cancers are rare, so they’re hard to study,” states Dr. “Studies such as these are a crucial first step in
Moke, who treats children with many of the developing a truly individualized approach to each
included cancers. “We have gathered data from the individual,” says Bruce Carleton, PharmD, who led the
greatest group ever of cisplatin-treated children and Canadian arm of this study. “Data provided by this
adolescents with a wide array of cancers,” she says. study will help oncologists identify patients that might
be at greater risk of hearing loss in order that protective
We found that how we infuse the drug can significantly strategies can be considered.”
alter the risk of side effects. Cisplatin has been used to
treat cancers in children and adults for more than fifty “We have developed these powerful tools to
years, but for the first time, we have insights into how effectively fight cancer,” says Dr. Orgel. “Now we
something as simple as adjusting our dosing approach can focus in on how to use these tools in a way that
may prevent hearing loss and still maintain effective maintains their power but reduces their footprint.”
treatments.” Source:
Etan Orgel, MD, MS, Study Lead Children’s Hospital Los Angeles
Overall, the study showed that 44 percent of
pediatric patients treated with cisplatin suffered
from moderate to severe hearing loss.

Research News
Scientists investigate how messenger substances

impact singular decision making
ccording to other studies, different determines the’E/I equilibrium’ between excitatory
parts of the brain are responsible for and inhibitory transmission action.
A different kinds of decisions. A research

team headed by Luca Franziska Kaiser
and Prof. Dr. Gerhard Jocham
in the HHU working
group’Biological Psychology of Decision
The researchers used magnetic resonance
spectroscopy to assess the concentrations of
Making’, and Dr. Theo Gruendler together

with colleagues in Magdeburg examined
the balance of the messenger substances
GABA and glutamate in 2 forms of
decision-making.
The background to the research was to
discover how different concentrations of
the substances influence the person
making the choice. GABA and glutamate in different cortical areas of
different subjects. The team then used the
On the one hand, the investigators looked information to correlate the ratio of the two
at’reward-based decisions’, which involve messenger substances with the individual decision-
maximizing reward by selecting the greater of two making behavior of the subjects. In the patch-
current options. Luca Kaiser gives a simple leaving scenario, subjects with a greater ratio of
example:” Where do I purchase coffee on my way GABA to glutamate in dACC were quicker to leave
to work, depending on the purchase price, quality a depleting resource. By comparison, people with
and whether the café is in my way?” higher concentrations of glutamate needed a larger
‘Patch-leaving decisions’ are about long-term quality improvement before choosing to leave their
tactical issues which have an extensive balancing of current patch. In the other scenario, subjects with
cost against gain. A good example of such a higher concentrations of GABA relative to
decision would be whether to move from glutamate in vmPFC exhibited significantly
Düsseldorf to Munich for a job offer. increased decision accuracy. They were more
reliable at selecting the higher-value option.
The job in Munich may offer a higher salary and a more
interesting role, but may also involve stress and the Luca Kaiser states:”Our results show a correlation
effort involved in finding a place to live and moving to between decision-making behavior and the balance
Munich as well as higher rents and the loss of social of 2 messenger substances in the brain. People with
contacts in Düsseldorf.” a higher ratio of excitation to inhibition in dACC
need more of an incentive to move away from their
Prof. Dr. Gerhard Jocham, Heinrich-Heine University status quo. By comparison, people with more
Duesseldorf GABA in vmPFC exhibit greater accuracy for
short-term conclusions.”
So there are lots of factors that influence this type
of decision. According to the literature, such Source:
decisions are made in the brain’s dorsal anterior
Heinrich-Heine University Duesseldorf
cingulate cortex, or dACC for short.
Journal reference:
Kaizer, L. F., et al. (2021) Dissociable roles of cortical excitation-inhibition

Both messenger materials glutamate and GABA balance during patch-leaving versus value-guided decisions. Nature
Communications. doi.org/10.1038/s41467-020-20875-w.
play a key role, and the ratio between the two

Product Launches
MedTrainer Introduces New clients can pick the features that are
LabComply to Simplify Lab most appropriate for their organization.
Once an organization becomes a
Compliance customer, a dedicated account success
manager is assigned to ensure a quick and
M ed Trainer, Redlands, Calif, released

LabComply, a cloud-based software
package that provides
comprehensive resource for managing all aspects
a
successful start-up that can be completed
within a matter of days after signing up.
For more information and to schedule a demo of
of CLIA testing. LabComply addresses the most
LabComply, visit MedTrainer.
common deficiencies found by CMS and
accreditation organizations such as staff
competency assessments, QC and maintenance Report Reveals Adoption
documentation, reagent and supply lot number and
expiration tracking, and verification of standard
of Digital Pathology
operating procedures. Accelerating
H amamatsu Photonics, Hamamatsu,

Japan, published a new market report
on perceptions and utilization of digital
pathology solutions, At the Tipping Point. With
findings from a survey of pathologists, laboratory
directors, and hospital leaders across the United
States, the report reveals that most see value in
digital pathology. However, a significant number of
Compliance with CLIA Waived testing, as defined pathology professionals aren’t leveraging whole
by the Manufacturer’s Instruction Use and Good slide scanning, and the large majority rely on
Laboratory Practices, is proving to be an expensive sending physical glass slides for secondary consults.
and time-consuming task for long-term care
facilities and other organizations that were “Technology has always been a part of bleeding-edge
provided covid-19 testing equipment and online healthcare, but pathology is an area where digital
training, but not a comprehensive method to imaging innovation has been slow to catch on,” says
manage compliance requirements. MedTrainer’s Don Ariyakumar, Hamamatsu’s product manager for
LabComply affordably simplifies required whole slide imaging and digital pathology. “Using glass
compliance processes for any type of organization slides is reliable, but slow and inefficient, and a lack of
that utilizes CLIA-Waived equipment. superior digital solutions, along with a lack of FDA-
cleared systems, for years made pathologists hesitant
“Quality testing and patient safety are essential for
to adopt digitization. Now, digitizing slides can be fast
laboratories,” says Jorge Fernandez, COO,
and produces high quality images that are relatively
MedTrainer, “We understand the challenges of
small in file size. It also creates an essential archive to
changing regulations on point of care testing
the original glass slides that can quickly and easily be
facilities. We developed LabComply based on
shared or retrieved for further diagnoses.”
customer need to the support training and
administrative tasks so that labs can efficiently and Key findings from the report include:
accurately manage their regulatory processes.”
 In-depth interviews with key opinion
MedTrainer customers can easily add the leaders
LabComply tools to their current portfolio of  Key factors that influence digital pathology
adoption
services.

Product Launches
 The value of whole slide scanning for
clinical diagnosis Binx Health Inks Distribution
 Impact of covid-19 for digital pathology Agreement for binx io
“Pathologists can’t sustain our profession now. It’s
impossible to scale up our work, do more
Launch
complicated testing and meet the demand of
precision medicine the way pathology is practiced
today, with the number of pathologists we have,
and with the microscope as the dominant tool,”
says Liron Pantanowitz, MD, director, anatomic
pathology, department of pathology, Michigan
B oston-based Binx Health has partnered
with global healthcare leader McKesson
for the sale and distribution of the binx io
platform in the United States.
Medicine, University of Michigan and a paid

consultant to Hamamatsu, in the report.
A first-of-kind FDA-cleared infectious disease

platform, the binx io provides results in about 30
minutes, which enables diagnosis and treatment of
chlamydia (CT) and gonorrhea (NG) to take place
in a single visit. The binx io’s test performance has
been demonstrated to be on par with central
laboratory testing.
“The pandemic has shown how important remote
Today, about 35 million CT/NG tests are
pathology is and has pushed healthcare leaders
processed at central laboratories, with virtually all
and clinicians to embrace and want to invest in
patients leaving a clinic before results are ready.
digital solutions,” adds Ariyakumar. “This truly is Under this traditional care model, up to 40% of
just the tipping point—we’re going to see the field patients who are subsequently determined to be
of pathology advance significantly as digital positive do not return for treatment once they leave
solutions are more widely embraced, leading to a the clinic, leading to further infection spread and
rise in assisted diagnosis and quality control comorbidities.
programs using AI algorithms. I’m excited to see
how this change will help push the boundaries of
medicine and healthcare as we know it.”
For more information, visit Hamamatsu
Photonics.
Featured image: Hamamatsu NanoZoomer for The company says the binx io is poised to change
whole slide imaging (Courtesy: Hamamatsu) all of that, by delivering results within the time
window of a typical OB-GYN visit.

Product Launches
Initial distribution of the binx io will be into that offered by currently available covid-19 tests.
settings that are certified to perform moderate or
high complexity diagnostic tests under the Clinical AnteoTech intends for the tests to be combined
Laboratory Improvement Amendments (CLIA). into a single multiplex test platform and be
available in as little as 6 to 9 months following
The binx io platform also may be used in satellite clinical trials and regulatory approvals.
point-of-care (POC) settings designated under such
moderate or high complexity certificates. Binx also AnteoTech is currently looking to build strategic
completed its CLIA waiver study and submitted a partnerships with medical device manufacturers to
request to the FDA in 2020 to classify the platform expedite commercialization. Once deployed, the
as CLIA waived, which, upon FDA clearance, will portable test could significantly reduce covid-19
spread by enabling detection and quarantine of
enable distribution to the 200,000+ CLIA-waived
locations nationwide. infected individuals before symptoms develop.
“At Binx we consider evidence-based care and “The development of this new platform
consumer convenience central to all we do,” says marks a critical step in our collective
Jeffrey Luber, Binx Health’s chief executive officer.
“Today’s announcement is a win-win-win for
journey to halt the spread of covid-19,”
clinics, patients, and the public health and we are says Derek Thomson, CEO of AnteoTech.
especially proud of this new distribution “By leveraging many years of expert insight
partnership for national reach.” in the form of our AnteoBind europium
For more information, visit Binx Health. nanoparticle technology and applying it to
Featured image: A first-of-kind FDA-cleared this unique challenge, we’re enabling
infectious disease platform, the binx io enables detection of the lower viral particle levels
diagnosis and treatment of chlamydia and seen in earlier stages of covid-19
gonorrhea to take place in a single visit. (Courtesy:
Binx Health)
infection—levels which aren’t detectable
with current gold-based diagnostics. As a
AnteoTech Developing POC result, we’re opening the possibility for
Lateral Flow Tests for Covid-19 better clinical decision-making and earlier
and Influenza direction of patients into quarantine to
curtail disease spread.”
For more information, visit AnteoTech.
B risbane, Australia-based AnteoTech, has

successfully developed proof-of-concept
covid-19
antigen and influenza
A and B point-of-care
lateral flow tests that
can detect the presence
of SARS-Cov-2 and
influenza in less than
15 minutes. The tests
utilize AnteoTech’s
patented AnteoBind
activated europium
technology and
provide significantly
higher sensitivity than

Product Launches
Featured image: Workflow for the AnteoTech BNK Reagent with Trucount Tubes has along with
COVID-19 antigen/Flu A&B multiplex other testing in determining the covid-19 patients’
test. Courtesy AnteoTech. risk of IMV and mortality at hospitalization.
As shown in peer-reviewed clinical studies, some
BD Assay to ID Covid-19 patients with covid-19 may exhibit a decrease of
Patients at Increased Risk of specific lymphocyte T-cell subsets (CD4+ and/ or
CD8+ T-cells), and this decrease is associated with
Intubation, Mortality Gets CE increased risk of IMV and mortality. Knowing a
patient’s accurate T-cell count, therefore, can be
Mark instrumental in informing the right course of
action, and the BD Multitest 6-Color TBNK
Reagent with BD Trucount Tubes may aid in these
B D (Becton, Dickinson and Company),

Eysins, Switzerland, announced the CE
mark of BD Multitest 6-Color TBNK
Reagent with BD Trucount Tubes with expanded
clinical application to help clinicians identify covid-
types of determinations.
Results from a study conducted by BD have shown
that a covid-19 patient’s risk for IMV and also
mortality is five to six times higher for T-cell
19 patients at increased relative risk of intubation subsets below cut-off levels of: CD4+ <250
with mechanical ventilation (IMV) and mortality at cells/µl and/or CD8+ <100 cells/µl compared to
hospital admission, in conjunction with clinical those that were above the cut-off.
findings and the results of other laboratory testing.
By providing deeper understanding of immune “The BD Multitest 6-Color TBNK Reagent with BD
responses, clinicians can better understand an Trucount Tubes assay’s new claim related to risks
appropriate course of action for patients while also of IMV and mortality may help clinicians better
prioritizing the use of precious hospital resources.
determine an appropriate course of action for
hospitalized covid-19 patients, which is a top
priority for this population,” says Puneet Sarin,
worldwide president of BD Biosciences. “BD
Biosciences has a long history of helping clinicians
and patients understand immune function, and
this new indication may help guide important care
decisions while also prioritizing resources.”
The BD Multitest 6-Color TBNK Reagent with BD
Trucount Tubes is used in conjunction with the BD
FACSLyric and BD FACSCanto II Clinical Flow
Cytometers for covid-19 clinical applications.
BD tools were utilized for research early in the

pandemic and early publications showed that the
BD Multitest 6-Color TBNK Reagent with For more information, visit BD.
Trucount Tubes was useful in assessing immune
status for covid-19 patients. Further clinical studies
have demonstrated clinically validated cut-off levels
and further refined the role BD Multitest 6-Color

Product Launches
with therapies including hormone treatment that
Study Validates Ability of can momentously impact their quality of life, while
Myriad Genetics’ Prolaris Test still appropriately treating their prostate cancer.”
to Guide Treatment for Prostate The new data comes from a second study following
previous data, recently published in Clinical
Cancer Genitourinary Cancer in January 2021, that
incorporated men treated surgically or with
radiation therapy. This new study combined a
M yriad Genetics, Salt Lake City, Utah,

announced additional data further
validating the prognostic power of its
Prolaris test and its ability to help accurately predict
Prolaris molecular risk score threshold with a
clinical model for predicting a patient’s benefit
from androgen deprivation therapy. Prolaris
determined that about one of every two men with
which men with more aggressive prostate cancer
will benefit from intensification of therapy and unfavorable intermediate-risk and one of every five
which patients may safely avoid such treatments. men with high-risk prostate cancer are below the
This second validation study was presented during proposed threshold associated with aggressive
an oral presentation at the American Society of disease and can therefore safely be treated with less
Clinical Oncology Genitourinary Cancer intense therapy while maintaining the benefits of
Symposium (ASCO-GU) by Jonathan Tward MD, treatment. Additional key findings revealed that the
PhD, associate professor in the Department of Prolaris test was an accurate predictor of
Radiation Oncology at the University of Utah. progression to metastatic disease.
“Myriad Genetics was the first
company to offer a test that directly
measures the molecular biology of an
individual patient’s prostate cancer,”
says Todd D. Cohen, MD, vice
president of Medical Affairs for
Urology at Myriad Genetics. “This
study by Dr. Tward and his team is
another strong validation of the
prognostic power of the Prolaris test
and our ongoing commitment to
providing healthcare professionals
with the tools needed to determine
the most effective treatments and
According to estimates by the American Cancer
monitoring strategies for each patient.”
Society, 248,530 new cases of prostate cancer are
expected to be diagnosed this year in the United In March 2020, the National Comprehensive
States. While early screening tests have helped Cancer Network updated its professional
reduce the mortality rate, they can often result in guidelines to include biomarker testing for
overdiagnosis and overtreatment of a disease that is unfavorable intermediate and high-risk patients
clinically insignificant. The Prolaris test can more with prostate cancer. With the updated guidelines,
accurately predict the aggressiveness of the cancer Prolaris was one of only two prognostic tests to be
allowing for more precise treatment and avoidance considered for those expanded indications.
of more intense therapies with a patient’s parallel Approximately 60% of men with prostate cancer
morbidities. currently have insurance or Medicare access to
Prolaris, and Myriad continues to work toward
“There are many viable treatment paths for men
expanding access so that every man who is facing
with prostate cancer,” says Tward. “This new data
difficult treatment decisions will be able to utilize
helps distinguish the most appropriate personalized
the full benefits of the test.
treatment path for each patient based on how their
specific tumor is behaving. For some men, this For more information, visit Myriad Genetics.
means being able to avoid overtreating patients

Product Launches
“Rapid testing continues to play an important role
Roche announces the upcoming in the fight against COVID-19, especially in places
launch of the SARS-CoV-2 Rapid when laboratory testing is not available and quick
results are needed, such as nursing homes,
Antigen Test Nasal allowing for healthcare facilities, and schools.” said Thomas
patient self-collection Schinecker, CEO Roche Diagnostics.
“The SARS-CoV-2 Rapid Antigen Test Nasal

provides patients with a more comfortable testing
R
oche today announced it has obtained
experience.”
the CE
mark for its
new SARS-CoV-
2 Rapid Antigen Test Nasal.
The test will be available in
countries accepting the CE
mark by mid-February 2021.
In comparison to the
existing Roche SARS-CoV-2
Rapid Antigen Test, the
SARS-CoV-2 Rapid Antigen
Test Nasal collects the
sample from the front area
of the nose instead of the nasopharynx, resulting in
a simplified and faster testing procedure. The launch is a partnership with
This testing method can help reduce overall
SD Biosensor Inc., with whom Roche has
patient discomfort, particularly in sensitive
individuals such as children, elderly people and/or also launched a SARS-CoV-2 Rapid
people with disabilities. Antibody Test in July and a SARS-CoV-2
Rapid Antigen Test in September 2020. SD
Biosensor, is currently preparing to submit
an Emergency Use Authorisation (EUA) to
the U.S. Food and Drug Administration
(FDA).
The test is the latest addition to Roche's
Besides being less invasive, the test also provides
comprehensive COVID-19 portfolio to
patients with the option to self-collect their nasal
sample under the supervision of a healthcare support healthcare systems in diagnosing
professional. SARS-CoV-2 infection.
Through reduced physical contact, this method of For more information: Roche
testing can help to decrease the risk of exposure to
the virus for healthcare professionals. Whether the
test could also be used without supervision of a
healthcare professional will depend on local
regulatory requirements.

Product Launches
Available as an early output from the company’s
Owlstone Medical Introduces test development process and supported by
Breath Biopsy Panel for scientific publications and Breath Biopsy client
study data, the panel will initially be offered for
Respiratory Diseases research use only as part of an expanded Breath
Biopsy products and services offering to
O
wlstone Medical, Cambridge, UK, supplement the Breath Biopsy Omni Assay. It will
introduced the Respiratory Diseases be used by pharmaceutical and academic/clinical
Research Use Only (RUO) Panel. The research clients to support therapeutic
breath biomarker panel, which is now development through characterization of disease
commercially available, is intended to support endotypes and monitoring response to therapy, and
research to distinguish between different types of to better understand the onset, development, and
chronic inflammatory airway diseases including exacerbation of disease.
asthma, chronic obstructive pulmonary disease
(COPD), and idiopathic pulmonary fibrosis (IPF), Building from this panel, an in vitro diagnostic
and to facilitate better therapeutic decision making (IVD) is intended to be developed to support
treatment decision making through
patient stratification and monitoring of
therapeutic response.
“The Respiratory Diseases RUO Panel
is the first to be commercially launched
by Owlstone Medical and opens an
important new phase in the application
of breath to address areas of high
clinical need,” says Billy Boyle, co-
founder and CEO at Owlstone
Medical.
and monitoring.
Owlstone Medical’s Respiratory Diseases RUO “Building on our recent announcement on
Panel consists of a set of biologically relevant the use of limonene as an EVOC probe in
volatile organic compounds (VOCs) that have been NASH/NAFLD, this panel further validates
linked to inflammatory respiratory diseases and can
be easily collected on breath to enable direct our strategy of identifying promising
characterization of disease biology in the lungs by biomarkers from multiple sources including
non-invasively sampling the airways. endogenous discovery, EVOC probes, and
in-licensing. We look forward to making
further announcements as our robust test
pipeline continues to develop.”
For more information, visit Owlstone Medical.

Product Launches
New Plant to Expand Particle Manufacturing

Capacity for Covid-19 Testing
C eres Nanosciences, Manassas, Va, has

completed the build-out of a new 12,000-
square-foot Advanced Particle
Manufacturing Plant in Innovation Park, Prince
“This new facility is a huge step up in capacity for
Ceres, giving us the ability to rapidly respond and
scale to current and future virus outbreaks and
testing needs,” says Ross Dunlap, Ceres
William County, Virginia. The new facility will be Nanosciences CEO.
capable of generating a supply of Ceres’ Nanotrap
Magnetic Virus Particles to enable more than 10 “We are thrilled that our new
million covid-19 tests per month, with room for manufacturing plant is also located within
added capacity in the future.
Innovation Park near our existing R&D
Nanotrap Magnetic Virus Particles improve facility,” says Ben Lepene, Ceres
diagnostic testing for covid-19 by eliminating the
Nanosciences CTO. “This means that we
need for RNA extraction kits, reducing sample
processing time, and improving the sensitivity of can ensure a stable supply of Nanotrap
the downstream assays in point-of-care systems, particles to our growing portfolio of
high-throughput laboratory tests, and wastewater customers while simultaneously
and pooled sample testing workflows. Nanotrap
maintaining our development efforts for
new Nanotrap products right down the
street.”
For more information, visit Ceres Nanosciences.
AnteoTech’s AnteoBind
Technology Supports
Covid-19 Home Test
Q ueensland, Australia-based AnteoTech’s

long-term customer Ellume, Brisbane,
Australia, has secured a $231.8 million
agreement with the United States government to
support accelerated manufacture of its covid-19
Magnetic Virus Particles also improve diagnostic home test. The test makes use of AnteoTech’s
testing for influenza virus, RSV, and variants of unique AnteoBind technology to support
SARS-CoV-2. significantly improved sensitivity, and is the first
rapid self-test for SARS-CoV-2 detection
The new facility was constructed in under 4 months authorized by the United States Food and Drug
with funding support from the National Institutes Administration (FDA) for use without a
of Health (NIH) Rapid Acceleration of Diagnostics prescription.
(RADx) initiative.

Product Launches
Through the
patented AnteoBind
technology and the
expertise and know-
how delivered via its
contract services in
assay development
and bioconjugation,
AnteoTech
continues to address
the pressing
challenges of the
point-of-care
diagnostics,
biopharmaceutical, and vaccine development
markets. The improved conjugation process increases the
performance for diagnostic assays, and enables
Read FDA Authorizes First Over-the-Counter superior quality control, candidate screening, and
Fully At-Home Diagnostic for Covid-19 efficacy-measurement processes in
With the help of AnteoTech’s AnteoBind biopharmaceutical and vaccine development. The
technology, the Ellume Covid-19 Home Test Ellume Covid-19 Home Test is an example of how
provides accurate results in 15 minutes or less, AnteoBind technology can aid in delivering
detecting SARS-CoV-2 in both symptomatic and conjugation stability, unmatched sensitivity and
asymptomatic individuals. Ellume’s offering is the batch-to-batch reproducibility—all while being
first test which utilizes AnteoBind to receive FDA manufactured at scale.
emergency use authorization (EUA). “Our recent emergency use authorization was a
“With the Ellume test receiving FDA key milestone in our mission to make a significant
contribution to global health,” says Sean Parsons,
authorization and subsequent significant
BSc, MBBS, chief executive officer of Ellume.
financial backing from the US government, “AnteoTech’s AnteoBind has greatly assisted us in
this is further evidence of the immense the development of a highly sensitive test that is
value the AnteoBind technology continues vital for an effective covid-19 mitigation strategy.
to bring to the life sciences industry for life- We look forward to our continued partnership with
changing solutions,” said Derek Thomson, AnteoTech as we deliver accurate diagnostic
solutions to the market.”
chief executive officer of AnteoTech. “The
capabilities of high-sensitivity diagnostics, AnteoTech’s AnteoBind can be purchased directly
as an AnteoBind-based ready-to-use kit to
such as Ellume’s Covid-19 Home Test, will streamline and improve the conjugation process, or
ultimately enable rapid and reliable is available through AnteoTech’s Assay
screening to minimize community spread, Development Services. The Assay Development
Services are focused on the application of
relieve burden on healthcare systems and
AnteoBind, and draw on the AnteoTech team’s
facilitate the reopening of economies.” extensive biomedical research and assay
AnteoBind is a nano-sized molecular glue used to development experience, particularly in difficult
facilitate simpler, faster, and more reliable conjugation assay design and quantitative assay
bioconjugation. design.
For more information on AnteoTech’s AnteoBind
technology and contract services, visit AnteoTech.

PUBLISHED ON: 25th February 2021 RNI NUMBER: UPENG/2017/73675

Microbioz, February 2021: India

Uploaded by

Document Information

Original Description:

Original Title

Copyright

Available Formats

Share this document

Share or Embed Document

Sharing Options

Did you find this document useful?

Is this content inappropriate?

Copyright:

Available Formats

Microbioz, February 2021: India

Uploaded by

Copyright:

Available Formats

2

Microbioz India, February 2021

The cover story of this month titled “Nebulization is safe, say

Added to this, the magazine has a unique article as a case

Dear subscribers, I trust you to discover some exciting topics

Microbioz India, February 2021 10

Microbioz India, February 2021 11

High Efficiency Aerosol Drug Delivery

Microbioz India, February 2021 12

 Berlinski A and Willis JR. Albuterol delivery by 4 different

 McPeck M. Improved Aerosol Drug Delivery with an

Microbioz India, February 2021 13

All you need to know

T all cancer burden, globally as well as in

estimates suggest every four minutes an Indian

Microbioz India, February 2021 14

Microbioz India, February 2021 15

Microbioz India, February 2021 16

Microbioz India, February 2021 17

Godrej & Boyce aims to strengthen Vaccine Cold Chain

G of the Godrej Group, has been

Microbioz India, February 2021 18

About Godrej Appliances: Godrej Appliances, a business unit of Godrej

Microbioz India, February 2021 20

Aster DM Healthcare launches a dedicated

A in the GCC and the third largest

Microbioz India, February 2021 21

Fortis brings together Cancer Survivors, shares

O undertook a distinctive approach to

Microbioz India, February 2021 22

Hunjan Hospital launches Mako Robotic Arm-

L city in Northern India to have the world’s

Microbioz India, February 2021 24

For more information:

Microbioz India, February 2021 25

100+ corporates sign up for Practo’s corporate health

racto, India’s leading integrated Through Practo, employees of the partnered

P significant growth in the demand for

Microbioz India, February 2021 26

technologically-assisted doctor consulting.

Microbioz India, February 2021 27

Arctoris Celebrates 5th Anniversary and Launches

Microbioz India, February 2021 28

Microbioz India, February 2021 29

Hydrogel injection could help fix harm to the

R based at NUI Galway, and

Microbioz India, February 2021 30

Microbioz India, February 2021 31

Study describes cisplatin-prompted hearing loss in

P now, studies have been too little and

Microbioz India, February 2021 32

Scientists investigate how messenger substances

A different kinds of decisions. A research

Making’, and Dr. Theo Gruendler together

Kaizer, L. F., et al. (2021) Dissociable roles of cortical excitation-inhibition

Microbioz India, February 2021 34

M ed Trainer, Redlands, Calif, released

H amamatsu Photonics, Hamamatsu,

Microbioz India, February 2021 35

Medicine, University of Michigan and a paid

A first-of-kind FDA-cleared infectious disease

Microbioz India, February 2021 36